Genscript Bio Gets Booster From Subsidiary’s New Cancer Drug 子公司新產(chǎn)品貢獻(xiàn)大 金斯瑞生物迎收成期
The company’s Legend Biotech unit has found recent success with Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy, which earned $134 million in its first nine months on the market 金斯瑞生物科技旗下傳奇生物開(kāi)發(fā)的CAR-T細(xì)胞治療藥Carvykti，上市9個(gè)月的銷售收入已超過(guò)1.34億美元。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.